By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AbbVie 

1 North Waukegan Road

North Chicago  Illinois  60064  U.S.A.
Phone: 1-800-255-5162 Fax: n/a


SEARCH JOBS

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company. AbbVie’s mission is to apply the expertise, dedication, and creativity of its people to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products — Imbruvica®, Venclexta™, and Empliciti™ — and a pipeline containing multiple promising new molecules that are being studied in nearly 200 clinical trials in 19 different types of cancer.

AbbVie is expanding its oncology hub on the West Coast, with three sites in the San Francisco Bay Area (Redwood City, South San Francisco, and Sunnyvale) focused on the discovery and development of novel oncology therapies. More than 1,000 AbbVie scientists, clinicians, and product developers with strong entrepreneurial roots work across these three sites. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments.

YEAR FOUNDED:

2013

LEADERSHIP:

CEO: Richard A. Gonzalez

CFO: William J. Chase

JOBS:

Please click here for Abbvie job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information..

FOLLOW ABBVIE:





Key Statistics


Email:
Ownership: Public

Web Site: AbbVie
Employees:
Symbol: ABBV
 









Company News
AbbVie (ABBV) Granted Priority Review In Japan For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C 3/14/2017 8:57:59 AM
Enanta Pharmaceuticals, Inc. Announces Japanese Ministry Of Health, Labour And Welfare Grants Priority Review For AbbVie (ABBV)’s Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C 3/14/2017 7:41:46 AM
Enanta Pharmaceuticals, Inc. Announces CHMP Grants Positive Opinion For An Eight-Week Treatment Option With AbbVie (ABBV)’s VIEKIRAX(Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C 2/27/2017 7:02:03 AM
AbbVie (ABBV) Receives CHMP Positive Opinion For Eight-Week Treatment Option With VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C 2/27/2017 6:38:40 AM
Drug Giants Like AbbVie (ABBV), Bristol-Myers Squibb (BMY) and Gilead (GILD) Turn to Well-Known Professors to Justify Its Outrageous Drug Prices 2/24/2017 5:58:42 AM
AbbVie (ABBV) Declares Quarterly Dividend 2/20/2017 6:45:13 AM
AbbVie (ABBV) Announces $5 Billion Increase To Stock Repurchase Program 2/17/2017 7:22:11 AM
A Look at Whether AbbVie (ABBV) Could Eventually Face the Same Issues as Gilead (GILD) 2/17/2017 6:36:22 AM
AbbVie (ABBV) Reports Full-Year and Fourth-Quarter 2016 Financial Results 1/27/2017 12:17:23 PM
AbbVie (ABBV) Release: Pharma Initiates Phase 2 Clinical Trial Programs For ABBV-8E12, An Investigational Anti-Tau Antibody, In Early Alzheimer's Disease And Progressive Supranuclear Palsy 1/25/2017 8:23:26 AM
12345678910...
//-->